Giving the immunotherapy Opdivo, made by Bristol Myers Squibb, to lung cancer patients before surgery can help prevent the disease from coming back, a new study says.
It’s a step toward what doctors have hoped cancer therapies that harness the immune system could ultimately do. It’s the same hope they have with every new drug, really: that they could be used in patients who were diagnosed early, perhaps curing a greater number.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
